-
By Bob Clark, AdvisorOne |
January 16, 2012
Wherein our intrepid blogger applies the logician's reductio ad absurdum argument to the current debate over applying the fiduciary standard to brokers, or not.
-
By Danielle Andrus, AdvisorOne |
May 3, 2011
To fully understand whether their costs are "reasonable," plan sponsors must have reliable and accurate data upon which to base their conclusions.
-
By Kenneth Silber |
October 1, 2009
Biotech has long been a high-risk, high-reward industry. It is an industry in which numerous firms, including many small-caps and start-ups, intensively research possible...
-
By Jenny Ivy |
March 5, 2009
In an effort to ease prescription drug costs in the United States - especially for older Americans - four senators introduced legislation yesterday that will...
-
By Janet Levaux, AdvisorOne |
January 1, 2009
Research Total Return Leaders Based on compounded annual price appreciation and dividends for the 10-year period ending Nov. 13, 2008, for stocks trading at or above...
-
By Janet Levaux, AdvisorOne |
March 1, 2008
Stocks in health care, including biotech and pharmaceuticals, are poised for higher levels in 2008 - thanks to present valuations, developing pipelines and acquisition horizons,...
-
By James Picerno |
November 1, 2006
"I spend 90 percent of my time on 5 percent of my clients' portfolios," says Dale Stevens, president of Grasswood Partners Inc., a Malibu, Calif....
-
By Staff Writer |
September 1, 2006
New products and other factors drive growth in health care/biotech, despite a cautious regulatory environment, analysts say. ----- Jason Kantor RBC Capital Markets 415-633-8565 Jason.kantor@rbccm.com Outlook: Fundamentally, I don't think the...
-
By Staff Writer |
May 23, 2006
Americans are growing larger and there seems to be no end in sight to this alarming trend.
-
By Susan B. Weiner |
March 1, 2006
HEALTH CARE FUNDS HAVEN'T BEEN WINNING ANY POPULARITY contests lately. Only $150 million flowed into the category in 2005, on the heels of a $1.45...
